On June 25, 2020 Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, reported the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17.00 per share (Press release, Fusion Pharmaceuticals, JUN 25, 2020, View Source [SID1234561490]). All of the shares are being offered by Fusion. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Fusion, are expected to be $212.5 million. In addition, Fusion has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 common shares at the initial public offering price.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The shares are expected to begin trading on the Nasdaq Global Market on June 26, 2020 under the ticker symbol "FUSN." The offering is expected to close on June 30, 2020, subject to the satisfaction of customary closing conditions.
Morgan Stanley, Jefferies, and Cowen, are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.
A registration statement relating to these securities became effective on June 25, 2020. The offering will be made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, Second Floor, New York, New York 10014; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone: (877) 547–6340 or by email at [email protected]; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, by telephone at (833) 297-2926, or by email at [email protected].
Fusion obtained a receipt for a final base PREP prospectus filed with the securities commissions or similar securities regulatory authorities in each of the provinces of Canada, other than Québec, on June 25, 2020. A copy of the Canadian supplemented PREP prospectus containing pricing information and other important information relating to Fusion’s common shares may, when available, be obtained from Morgan Stanley Canada Limited and Jefferies Securities, Inc., care of the Morgan Stanley and Jefferies contact details referred to above. Prospective Canadian investors should clearly indicate in their request that they are a Canadian prospective investor and are requesting a copy of the Canadian supplemented PREP prospectus. When available, a copy of the Canadian supplemented PREP prospectus will be available on the SEDAR website at www.sedar.com under Fusion’s profile.